

PRESS RELEASE

CUTISS to participate in Jefferies London Healthcare Conference 2022

Switzerland, 7 November 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced that the company is invited to the upcoming Jefferies London Healthcare Conference, taking place November 15 – 17, 2022.

Dr Daniela Marino, Chief Executive Officer and co-founder at CUTISS, will attend the conference and hold one-to-one meetings with registered members of the investor community which includes leading global executives, institutional investors, and private equity investors.

The Jefferies Healthcare Conference is the largest healthcare-dedicated investor conference in Europe covering pharma, biotech, medtech and healthcare services. The past conference saw 550 companies and 3,000 attendees from Americas, Europe, Middle East, Africa, and Asia join the event.

About CUTISS AG

[CUTISS](#) is a Swiss clinical-stage life sciences company focused on regenerative medicine and skin tissue engineering. It is developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries.

The lead product denovoSkin™ promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase II clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.

CUTISS is also developing the world's first machines that can automate the entire production process of the personalized skin graft. The company's knowledge in skin bio-engineering and biology offers several growth opportunities in regenerative medicine.

Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children's Hospital and was a member of the accelerator Wyss Zurich until February 2022. Headquartered at the Bio-Technopark in Zurich-Schlieren, it won the Top 100 Swiss Startup Award 2020, and has raised over CHF 55 million from private investors, family offices and public bodies.

Media contacts

Cabinet Privé de Conseils (Switzerland)

Toomas Kull kull@cpc-pr.com | +41 767 480 174

Nick Miles miles@cpc-pr.com | +41 796 787 626